Marksans Pharma
Marksans Pharma Limited, headquartered in India, is a prominent player in the global pharmaceutical industry, specialising in the development and manufacturing of generic and over-the-counter (OTC) products. Founded in 2001, the company has established a strong presence in key markets, including North America, Europe, and Asia, with a commitment to quality and innovation.
With a diverse portfolio that includes formulations across various therapeutic areas, Marksans Pharma stands out for its robust research and development capabilities. The company is known for its unique approach to product development, ensuring compliance with international regulatory standards. Marksans has achieved significant milestones, including successful product launches and strategic partnerships, solidifying its position as a trusted name in the pharmaceutical sector.
-12 vs industry average
Marksans Pharma’s score of 26 is higher than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Marksans Pharma?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Marksans Pharma's reported carbon emissions
In 2025, Marksans Pharma reported total carbon emissions of approximately 21,868,979 kg CO2e, comprising 19,912,486 kg CO2e from Scope 1 and 1,530,493 kg CO2e from Scope 2 emissions. Notably, there were no reported Scope 3 emissions for this year. The previous year, 2024, saw a total of approximately 23,130,250 kg CO2e, with all emissions attributed to Scope 1, as no Scope 2 or Scope 3 data was disclosed. In 2023, the company reported approximately 22,110,220 kg CO2e, again solely from Scope 1 emissions. Marksans Pharma has not set specific reduction targets or climate pledges, indicating a potential area for future commitment. The absence of Scope 3 emissions data suggests that the company may need to enhance its reporting practices to align with industry standards. Overall, while Marksans Pharma has made strides in tracking its emissions, the lack of comprehensive data and reduction initiatives highlights opportunities for improvement in its climate strategy.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Marksans Pharma’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Marksans Pharma yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Marksans Pharma
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project